SCHEMBL30357723

SCHEMBL30357723

CCN(C)Cc1ccc(-n2cnc(-c3nc(NC4CCN(S(C)(=O)=O)CC4)ncc3C(F)(F)F)c2)c(Cl)c1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CCNE1 P24864 19/20 0.61
▸ CDK2 P24941 19/20 0.61
▸ CDK1 P06493 15/20 0.61
▸ CCNB1 P14635 15/20 0.61
▸ CCND1 P24385 13/20 0.61
▸ CDK6 Q00534 13/20 0.61
▸ CDK4 P11802 12/20 0.61
▸ CCND3 P30281 12/20 0.61
▸ CCNT1 O60563 6/20 0.61
▸ CDK7 P50613 6/20 0.61
▸ CDK9 P50750 6/20 0.61
▸ CCNH P51946 6/20 0.61
▸ MNAT1 P51948 6/20 0.61
▸ PTK2 Q05397 1/20 0.44
▸ CCNB2 O95067 2/20 0.44
▸ CCNE2 O96020 2/20 0.44
▸ CDK5 Q00535 2/20 0.44
▸ CDK5R1 Q15078 2/20 0.44
▸ CCNB3 Q8WWL7 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22977325 1.00 CCNE1 (0.61) CCNE1CDK2CDK1CCNB1CCND1
SCHEMBL22976997 0.94 CCNE1 (0.62) CCNE1CDK2CDK1CCNB1CCND1
SCHEMBL22977051 0.94 CCNE1 (0.56) CCNE1CDK2CDK1CCNB1CCND1
SCHEMBL29821150 0.94 CCNE1 (0.56) CCNE1CDK2CDK1CCNB1CCND1
SCHEMBL30449353 0.91 CCNE1 (0.64) CCNE1CDK2CDK1CCNB1CCND1
SCHEMBL22977182 0.91 CCNE1 (0.64) CCNE1CDK2CDK1CCNB1CCND1
SCHEMBL22977342 0.91 CCNE1 (0.59) CCNE1CDK2CDK1CCNB1CCND1
SCHEMBL22977431 0.90 CCNE1 (0.61) CCNE1CDK2CDK1CCNB1CCND1
SCHEMBL22977334 0.90 CCNE1 (0.64) CCNE1CDK2CDK1CCNB1CCND1
SCHEMBL22977395 0.90 CCNE1 (0.64) CCNE1CDK2CDK1CCNB1CCND1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250243183-A1 IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS INCYTE CORPORATION 2025-07-31 — — US disclosed
US-12312331-B2 Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors INCYTE CORPORATION (US) 2025-05-27 — — US disclosed
US-20230024173-A1 IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS INCYTE CORPORATION 2023-01-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12312331-B2 Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors CDK2, CDK4, CDK2AP2 CCNE1 43/4885CDK2 1/4885CDK1 7/4885
US-20230024173-A1 IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS CDK2, CDK4, CDK2AP2 CCNE1 43/4885CDK2 1/4885CDK1 7/4885
US-20250243183-A1 IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS CDK2, CDK4, CDK2AP2 CCNE1 43/4885CDK2 1/4885CDK1 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback